key: cord-0750282-tyj0se8c
authors: Sangalli, Davide; Martinelli-Boneschi, Filippo; Versino, Maurizio; Colombo, Irene; Ciccone, Alfonso; Beretta, Simone; Marcheselli, Simona; Altavilla, Riccardo; Roncoroni, Mauro; Beretta, Sandro; Lorusso, Lorenzo; Cavallini, Anna; Prelle, Alessandro; Guidetti, Donata; La Gioia, Sara; Santalucia, Paola; Zanferrari, Carla; Grampa, Giampiero; D'Adda, Elisabetta; Peverelli, Lorenzo; Colombo, Antonio; Salmaggi, Andrea
title: Impact of SARS-CoV-2 infection on acute intracerebral haemorrhage in northern Italy
date: 2021-05-05
journal: J Neurol Sci
DOI: 10.1016/j.jns.2021.117479
sha: e350955c5e09016ea2ffa791aa37c7a73bdfc221
doc_id: 750282
cord_uid: tyj0se8c

INTRODUCTION: Growing evidence has been published as to the impact of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) on cerebrovascular events over the last few months, with considerable attention paid to ischemic strokes. Conversely, little is known about the clinical course of intracerebral haemorrhage (ICH) and simultaneous SARS-CoV-2 infection. METHOD: The Italian Society of Hospital Neurosciences (SNO) promoted a multicentre, retrospective, observational study (SNO-COVID-19), involving 20 Neurological Departments in Northern Italy. Clinical data on patients with acute cerebrovascular diseases, admitted from March 1st to April 30th, 2020, were collected. A comparison was made of the demographical and clinical features of both SARS-CoV-2 positive and negative patients with ICH. RESULTS: 949 patients were enrolled (average age 73.4 years; 52.7% males); 135 patients had haemorrhagic stroke and 127 (13.4%) had a primary ICH. Only 16 patients with ICH (12.6%) had laboratory confirmed SARS-CoV-2 infection, both symptomatic and asymptomatic. SARS-CoV-2 related pneumonia or respiratory distress (OR 5.4), lobar location (OR 5.0) and previous antiplatelet or anticoagulant treatment (OR 2.9) were the only factors significantly associated with increased mortality in ICH. SARS-CoV-2 infection, regardless of respiratory involvement, led to a non-significantly increased risk of in-hospital death (37.5% vs 23.4%, p = 0.2). DISCUSSION: ICH patients with COVID-19 did not experience an increase in mortality as striking as ischemic stroke. The inflammatory response and respiratory complications could justify the slight increase of death in ICH. Bleeding sites and previous antiplatelet or anticoagulant treatment were the only other predictors of a worse outcome.

In the last few days of February 2020, an extensive outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) involved Northern Italy. In the two months that followed, the disease caused by SARS-CoV-2, named COVID-19 [1] , spread quickly. The spectrum of SARS-CoV-2 infection severity varied widely and a substantial number of patients had neurological manifestations [2] [3] [4] . Particularly, evidence is emerging concerning both the frequency and the outcome of cerebrovascular complications. One of the first single centre studies described a 4.6% risk of ischemic stroke and a 0.5% risk of intracerebral haemorrhage in patients with COVID-19 [5] . Further analysis estimated the occurrence of cerebrovascular events in COVID-19 patients, ranging from 0.9% to 1.8% [6] [7] [8] . The proportion of ischaemic versus haemorrhagic strokes is not significantly skewed as compared to the pre-COVID-19 era or to SARS-CoV-2 negative patients admitted to hospitals during the pandemic. Conversely, a striking increase in intra-hospital mortality is being reported, especially for SARS-CoV-2 positive patients affected by ischaemic stroke, whereas data for haemorrhagic stroke are scanty [8] . The increased risk of stroke and mortality in systemic infection is not exclusive to SARS-CoV-2: early changes of clotting, platelet activation and artery dysfunction during severe sepsis may be involved in thrombotic-related events and act as additional risk factors [9] .

Our study addressed the clinical course of patients with cerebral haemorrhage and simultaneous SARS-CoV-2 infection, paying particular attention to both SARS-CoV-2 positive and negative patients hospitalized during the pandemic.

The Italian Society of Hospital Neurosciences (SNO) promoted a multicentre, retrospective, observational study (SNO-COVID-19), involving 20 Neurological Departments in Northern Italy. Nineteen were in Lombardy region, the most affected area in Italy, and one centre was in the neighbouring region of Emilia. It included both hospitals designated as hubs for cerebrovascular diseases and those promptly converted into predominantly COVID-19 Hospitals. Ethical approval for the study was obtained from the Local Research Ethics Committee and the single Ethical Committees of participating centres.

Patient information was collected for age and gender, type of cerebrovascular accident, with OCSP or TOAST classification of ischemic stroke [10, 11] , whereas lobar or typical location was considered for ICH; hematologic parameters (CRP, D-dimer and total lymphocyte count), previous antiplatelet or anticoagulant drugs, functional outcome at discharge (using a four-grade scale) and discharge arrangement. Information about COVID-19 was also included: incidental or symptomatic finding of SARS-CoV-2, extent of pulmonary involvement, whether continuous positive airway pressure (CPAP) and/or endotracheal tube was required, neuropsychiatric symptoms and the cause of death. The local investigators provided the coordinating centre ("Alessandro Manzoni" Hospital) with all the data for analysis. (Figure 1) . Among all ICH patients, 16 (12.6%) were diagnosed as SARS-CoV-2 positive by nasopharyngeal swab: 6 patients were asymptomatic cases of COVID-19 infection. There were no gender differences. The outcome in SARS-CoV-2 positive patients was generally worse, but not to a statistically significant extent: 1 (6.3%) was discharged without any symptoms, 5 (31.3%) with mild disability but able to walk, 4 (25%) unable to walk even with assistance. In the group of negative patients, 16 

The increased mortality during hospitalization in patients with ICH and COVID-19 was not as marked as that observed in ischaemic stroke [6, 8] or myocardial infarction [12] , despite ICH mortality is known to be higher compared to other cerebrovascular diseases [13] . This finding is also strikingly different from patients with acute ischemic stroke recruited in our study in the same period, whose mortality was increased fourfold by COVID-19. Inflammation, hypoxia and pro-thrombotic activity linked to SARS-CoV-2 may play a relevant role in the clinical and biological evolution of tissue damage, and this role may be more prominent in ischaemic than in haemorrhagic stroke [14, 15] , despite recent evidence of multiple cerebral microbleeds in critically ill or deceased COVID-19 patients [16] . In our cohort a massive inflammatory response with increased CRP values appeared to be related with a worse prognosis in SARS-CoV-2 patients, while elevated D-dimer levels increased mortality risk in both SARS-CoV-2 positive and negative patients. Nonetheless, this response did not affect the incidence of delirium in COVID-19 patients. This finding might be related to the comparatively low number of patients with SARS-CoV-2 infection included or it might also suggest that systemic inflammation in the context of COVID-19 impact less severely on haemorrhagic cerebral lesions [6, 8] . Delirium in SARS-CoV-2 infection is probably a heterogeneous entity, encompassing rare cases of true encephalitis and more frequent cases of encephalopathy: a recent report underscored the relevance of cytokine release within the CNS (TNF-α, IL-6 and IL-8 levels in the CSF) in the differential diagnosis between COVID-19 encephalopathy and encephalitis [17] . Despite multiple pathways allowing potential entry into the CNS of the virus (viremia, trans-nasal and retrograde axonal transport in neurons), most neuropathology studies have failed to detect virus in all the patients with neuropsychiatric symptoms.

During the COVID-19 outbreak, reduced/delayed admissions for cerebrovascular events [18] and pandemicinduced constraints in availability of diagnostic and therapeutic facilities might have contributed to increase mortality for cerebrovascular accidents. However, as most studies carried out on stroke and COVID-19 have no internal control groups or historical data to count on, it is not possible to make a precise evaluation of the impact these factors have [19] . Conversely, our study provides an internal control group of SARS-CoV-2 negative patients with ICH admitted to neurology units in the same period, thus eliminating pandemic-related changes in overall mortality. In our cohort, in-hospital mortality in ICH was low, and gender distribution and haemorrhage location were not significantly different in SARS-CoV-2 patients [8] . These findings may be partially explained by our recruitment strategy from neurological departments with a possible underdiagnosis of brain haemorrhages occurring in seriously ill patients admitted to acute non-neurological care wards and Intensive Care Unit for COVID-19.

Overall, as is well known, our study confirms that age, ICH sites and previous antiplatelet or anticoagulant treatment are predictors of in-hospital death. Unlike ischemic stroke, ICH in SARS-CoV-2 patients led only to a slight increase in mortality, mainly due to respiratory involvement, whilst bleeding location, previous therapies and gender do not seem to impact differently in SARS-CoV-2 positive and negative patients. 

COVID-19: the first documented coronavirus pandemic in history

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological Involvement in COVID-19 and Potential Mechanisms: A Review

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol

Stroke Risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases

Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study

Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry

Risk factors for stroke in patients with sepsis and bloodstream infections

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial

Trial of Org 10172 in Acute Stroke Treatment

Classification and natural history of clinically identifiable subtypes of cerebral infarction

Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

SPREAD -Stroke Prevention and Educational Awareness Diffusion

The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries

Lymphocyte Ratio Predicts the Outcome of Acute Intracerebral Haemorrhage

Large and Small Cerebral Vessel Involvement in Severe COVID-19: Detailed Clinical Workup of a Case Series

SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses

Italian Stroke Organization. Reduced Admissions for Cerebrovascular Events During COVID-19 Outbreak in Italy. Stroke

Cerebrovascular Complications of COVID-19. Stroke